Regulatory Bayer plans filings for cardiac amyloidosis imaging agent PharmaphorumArmed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.CardiovascularRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaphorum Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis. Cardiovascular Read full story Post navigation Previous: Roche buys AI-powered diagnostics player PathAINext: Angelini inks $4.1B Catalyst buy to enter US rare disease market Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026